

## Sensorion Announces the Appointment of Laurene Danon as Chief Financial Officer

**Montpellier, June 27, 2024, 7.30 am CET – Sensorion (FR0012596468 – ALSEN)** a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the appointment of Ms Laurene Danon as Chief Financial Officer.

Laurene brings to Sensorion more than 15 years of experience in investment banking and international equity capital markets. A graduate of HEC, she began her career in London with the investment bank J.P. Morgan, in corporate finance advisory, before specializing in equity capital markets at J.P. Morgan and later at Jefferies International. Prior to joining Sensorion, she founded the strategic advisory firm Concorde Advisory, where she supported and managed the execution of strategic corporate finance projects for her clients. In total, Laurene has led executions for 70 transactions totaling over \$35 billion raised.

Laurene was well known to the Sensorion team, having advised the company on recent capital increases.

**Laurene Danon, Chief Financial Officer of Sensorion, said:** *"I am delighted to have the opportunity to join Sensorion at a pivotal moment in its history, marked by a strong acceleration of its programs, particularly in gene therapy. These programs are currently receiving strong support from the medical community, patients and their families, as well as investors. I am determined to work with the whole team at Sensorion to further develop highly innovative therapies for hearing disorders, a significant global unmet medical need."*

**Nawal Ouzren, Chief Executive Officer of Sensorion, said:** *"I am excited to welcome Laurene whose appointment represents excellent news for Sensorion and comes at a time of significant opportunity and growth for Sensorion. She brings a wealth of knowledge that will play a paramount role in supporting advances in Sensorion's pipeline. With her proven expertise of international capital markets, she will be a great addition to our management's team and will immensely contribute in Sensorion's mission to bring potentially life-transformative solutions to people living with hearing disorders."*

### About Sensorion

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.

It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.

Sensorion's portfolio also comprises clinical-stage small molecule programs for the treatment and prevention of hearing loss disorders. Sensorion's clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, in a study of SENS-401 in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022.

[www.sensorion.com](http://www.sensorion.com)



**Press release**

**Contacts**

**Investor Relations**

Noémie Djokovic, Investor Relations and  
Communication Associate

[ir.contact@sensorion-pharma.com](mailto:ir.contact@sensorion-pharma.com)

**Press Relations**

Ulysse Communication

Bruno Arabian / 00 00(0)6 87 88 47 26

[barabian@ulyссе-communication.com](mailto:barabian@ulyссе-communication.com)

Nicolas Entz / 00 33 (0)6 33 67 31 54

[nentz@ulyссе-communication.com](mailto:nentz@ulyссе-communication.com)

Label: **SENSORION**  
ISIN: **FR0012596468**  
Mnemonic: **ALSEN**



**Disclaimer**

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2023 full year report published on March 14, 2024, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.